MedTrace Logo

Repeat Dose Safety Study for Compound to Treat Anemia

NCT00840320 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2017-06-22

No results posted yet for this study

Summary

The purpose of this study is to characterize the safety and tolerability of repeat doses of compound 1278863A in healthy subjects.

Conditions

Interventions

DRUG

1278863

15mg, 25mg, 50mg, 150mg

DRUG

Placebo

matching placebo

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-03-13
Primary Completion
2009-09-02
Completion
2009-09-02

Countries

  • Australia

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00840320 on ClinicalTrials.gov